Jenny Xiao

Illumina (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Erik Bjeldanes

Agilent Technologies (United States)

Paul K. Wolber

Agilent Technologies (United States)

Anne Bergstrom Lucas

Agilent Technologies (United States)

Glenda Delenstarr

Agilent Technologies (United States)

Kaho Minoura

Agilent Technologies (Japan)

Lou Welebob

Agilent Technologies (United States)

Jessica P. Hampton

Stanford University

Mengchi Wang

Sun Yat-sen University

Matthew H. Porteus

Stanford University

Vandan Shah

Geisinger Medical Center

Cooperative Institutions

Agilent Technologies (United States)

Stanford University

Illumina (United States)

California Institute for Regenerative Medicine

Palo Alto University

Hewlett-Packard (United States)

University of California, San Francisco

New York University

Johns Hopkins University

University of California, San Diego

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Construction of a random circular permutation library using an engineered transposon

Analytical Biochemistry (2015)

Brennal Pierre Vandan Shah Jenny Xiao Jin Ryoun Kim

Sequence (biology)

10.1016/j.ab.2014.12.011

Cite

Citations (8)

Comparison of Hybridization and Wash Procedures for Agilent 60mer Oligonucleotide Microarrays

Jenny Xiao Anne Bergstrom Lucas Glenda Delenstarr Rhoda Argonza-Barrett Erik Bjeldanes

10.14869/toxp.32.0.208.0

Cite

Citations (0)

Comparison of Hybridization and Wash Procedures for Agilent 60mer Oligonucleotide Microarrays(Others, Proceedings of the 32nd Annual Meeting)

The Journal of Toxicological Sciences (2005)

Jenny Xiao Anne Bergstrom Lucas Glenda Delenstarr Rhoda Argonza Erik Bjeldanes

Source

Cite

Citations (0)

Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells

Nature Communications (2022)

M. Kyle Cromer Valentin Barsan Erich Jaeger Mengchi Wang Jessica P. Hampton

Abstract As CRISPR-based therapies enter the clinic, evaluation of safety remains a critical and active area of study. Here, we employ a clinical next generation sequencing (NGS) workflow to achieve high sequencing depth and detect ultra-low frequency variants across exons of genes associated with cancer, all exons, and genome wide. In three separate primary human hematopoietic stem and progenitor cell (HSPC) donors assessed in technical triplicates, we electroporated high-fidelity Cas9 protein targeted to three loci (AAVS1, HBB , and ZFPM2 ) and harvested genomic DNA at days 4 and 10. Our results demonstrate that clinically relevant delivery of high-fidelity Cas9 to primary HSPCs and ex vivo culture up to 10 days does not introduce or enrich for tumorigenic variants and that even a single SNP in a gRNA spacer sequence is sufficient to eliminate Cas9 off-target activity in primary, repair-competent human HSPCs.

10.1038/s41467-022-32233-z

Cite

Citations (37)